ストックスクリーナーアプリを入手
34.77
1.40%
0.48
アフターアワーズ：
34.77
前日終値:
$34.29
開ける：
$34.08
24時間の取引高:
2.73M
Relative Volume:
1.28
時価総額：
$9.93B
収益：
$2.01B
当期純損益:
$349.99M
株価収益率:
122.73
EPS:
0.2833
ネットキャッシュフロー:
$166.29M
1週間 パフォーマンス:
+21.02%
1か月 パフォーマンス:
+30.42%
6か月 パフォーマンス:
+58.77%
1年 パフォーマンス:
+65.57%
1日の値動き範囲:
$34.08
$35.15
1週間の範囲:
$31.18
$35.15
52週間の値動き範囲:
$19.20
$35.15
Exelixis Inc Stock (EXEL) Company Profile
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
Exelixis (NASDAQ:EXEL) Sets New 52-Week HighTime to Buy? - MarketBeat
Here is Why Growth Investors Should Buy Exelixis (EXEL) Now - Yahoo Canada Finance
Earnings Estimates Rising for Exelixis (EXEL): Will It Gain? - Yahoo Finance
Capital Management Corp VA Increases Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis's SWOT analysis: oncology leader's stock poised for growth - Investing.com
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook - MSN
3 Magnificent Stocks Under $100 to Buy in November - The Motley Fool
New York State Teachers Retirement System Raises Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis cso sells stock worth $36,486 By Investing.com - Investing.com Australia
Dana Aftab Sells 1,162 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock - MarketBeat
Exelixis cso sells stock worth $36,486 - Investing.com
Exelixis (NASDAQ:EXEL) Issues Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Trend Tracker for (EXEL) - Stock Traders Daily
Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Exelixis price target raised to $38 from $33 at Truist - MSN
Stephens Investment Management Group LLC Has $98.78 Million Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine - Seeking Alpha
Exelixis, Inc. (NASDAQ:EXEL) Q3 2024 Earnings Call Transcript - Insider Monkey
Exelixis stock hits 52-week high at $31.3 amid robust growth - Investing.com Australia
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St
Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance - Investing.com
Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance By Investing.com - Investing.com UK
Exelixis price target raised to $36 from $33 at Piper Sandler - Yahoo Finance
DekaBank Deutsche Girozentrale Acquires 30,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Exelixis EVP Jeffrey Hessekiel sells $709,750 in stock - Investing.com
Exelixis stock hits 52-week high at $31.3 amid robust growth By Investing.com - Investing.com South Africa
Royal Bank of Canada Reiterates Outperform Rating for Exelixis (NASDAQ:EXEL) - MarketBeat
Exelixis shares target lifted, retains equal weight on strong Q3 results - Investing.com
Exelixis (NASDAQ:EXEL) Hits New 1-Year High Following Analyst Upgrade - MarketBeat
Stephens Boosts Exelixis (NASDAQ:EXEL) Price Target to $29.00 - MarketBeat
Piper Sandler boosts Exelixis stock target on earnings beat and optimistic revenue outlook - Investing.com UK
FY2024 EPS Estimates for Exelixis Reduced by Leerink Partnrs - MarketBeat
Exelixis stock sees upside with cabozantinib’s patent extension and label expansion - Investing.com UK
Exelixis Reports Strong Q3 2024 Earnings and Pipeline Expansion - TipRanks
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Exelixis Earnings: Raising Valuation on Improved Outlook Thanks to Pipeline Candidate Zanzalintinib - Morningstar
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
No-Moat Exelixis Focuses on Developing Pipeline to Offset Future Generic Entry for Cabozantinib - Morningstar
Exelixis: Q3 Earnings Snapshot - The Advocate
Exelixis (EXEL) Q3 2024 Earnings Call Transcript - Yahoo! Voices
Exelixis Inc (EXEL) Q3 2024 Earnings: EPS of $0.40 Beats Estimat - GuruFocus.com
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Exelixis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
China Universal Asset Management Co. Ltd. Buys 20,641 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Q4 Earnings Estimate for Exelixis Issued By Leerink Partnrs - MarketBeat
Assenagon Asset Management S.A. Sells 588,870 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Yahoo Finance
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):